Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer

Haruhito Azuma, Teruo Inamoto, Kiyoshi Takahara, Naokazu Ibuki, Hayahito Nomi, Kazumasa Komura, Hirofumi Uehara, Koichiro Minami, Kazuhiro Yamamoto, Yoshifumi Narumi

Research output: Contribution to journalArticle

Abstract

Overall, >900 patients have been treated at Osaka Medical College (Takatsuki, Osaka, Japan) using the novel approach of balloon-occluded arterial infusion (BOAI) to deliver an extremely high concentration of the anticancer agents cisplatin (CDDP)/gemcitabine to the pelvis (referred to as the OMC-regimen), together with pelvic irradiation. In a previous study, overall survival (OS) rate was significantly higher in this treatment group compared with that in a control group receiving total cystectomy (79.6 vs. 49.6%, respectively, at 10 years). It was speculated that intensive treatment of the pelvic area may aid in preventing metastasis, and thus the present study focused on the effect of this therapy in patients with lymph node metastasis (LN + ). A total of 102 patients with advanced LN + bladder cancer received tetramodal therapy (termed the Azuma regimen), comprising radical transurethral resection of the bladder tumor, systemic chemotherapy, BOAI and pelvic irradiation. Patients who failed to achieve a complete response (CR) underwent secondary BOAI with an increased amount of CDDP and/or gemcitabine with/without hemodialysis. A CR was achieved in 57.8% (59/102) of patients in total, and in 78.8% (41/52) of patients with N1 and Tis-3 disease. Among the complete responders, 81.4% (48/59) of patients retained their bladders with no evidence of recurrence or metastasis within a mean follow-up period of 121 weeks. Stages N2-3 and T4 were determined as significant risk factors for treatment failure in addition to survival. Notably, the 10-year overall survival rates in N1, Tis-3, and N1 and Tis-3 were 67.6% (vs. 33.6% in N2-3; P=0.0003), 61.5% (vs. 37.9% in T4; P=0.0485) and 75.1% (vs. 35.5% in N2-3 or T4; P=0.0002), respectively. No patients suffered from grade IV toxicities. In conclusion, the Azuma regimen may be a feasible option for patients with LN + disease. The use of intensive treatment in the pelvic area may serve an important role in outcome improvement, and the prevention of metastasis may be its mechanism.

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalInternational Journal of Oncology
Volume54
Issue number1
DOIs
Publication statusPublished - 01-01-2019

Fingerprint

Urinary Bladder Neoplasms
Antineoplastic Agents
Lymph Nodes
gemcitabine
Neoplasm Metastasis
Therapeutics
Survival Rate
Cystectomy
Treatment Failure
Pelvis
Cisplatin
Renal Dialysis
Japan
Urinary Bladder
Recurrence
Drug Therapy
Control Groups
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Azuma, Haruhito ; Inamoto, Teruo ; Takahara, Kiyoshi ; Ibuki, Naokazu ; Nomi, Hayahito ; Komura, Kazumasa ; Uehara, Hirofumi ; Minami, Koichiro ; Yamamoto, Kazuhiro ; Narumi, Yoshifumi. / Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer. In: International Journal of Oncology. 2019 ; Vol. 54, No. 1. pp. 167-176.
@article{be5f7a4f2c414dcc848b1a407cc1fdde,
title = "Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer",
abstract = "Overall, >900 patients have been treated at Osaka Medical College (Takatsuki, Osaka, Japan) using the novel approach of balloon-occluded arterial infusion (BOAI) to deliver an extremely high concentration of the anticancer agents cisplatin (CDDP)/gemcitabine to the pelvis (referred to as the OMC-regimen), together with pelvic irradiation. In a previous study, overall survival (OS) rate was significantly higher in this treatment group compared with that in a control group receiving total cystectomy (79.6 vs. 49.6{\%}, respectively, at 10 years). It was speculated that intensive treatment of the pelvic area may aid in preventing metastasis, and thus the present study focused on the effect of this therapy in patients with lymph node metastasis (LN + ). A total of 102 patients with advanced LN + bladder cancer received tetramodal therapy (termed the Azuma regimen), comprising radical transurethral resection of the bladder tumor, systemic chemotherapy, BOAI and pelvic irradiation. Patients who failed to achieve a complete response (CR) underwent secondary BOAI with an increased amount of CDDP and/or gemcitabine with/without hemodialysis. A CR was achieved in 57.8{\%} (59/102) of patients in total, and in 78.8{\%} (41/52) of patients with N1 and Tis-3 disease. Among the complete responders, 81.4{\%} (48/59) of patients retained their bladders with no evidence of recurrence or metastasis within a mean follow-up period of 121 weeks. Stages N2-3 and T4 were determined as significant risk factors for treatment failure in addition to survival. Notably, the 10-year overall survival rates in N1, Tis-3, and N1 and Tis-3 were 67.6{\%} (vs. 33.6{\%} in N2-3; P=0.0003), 61.5{\%} (vs. 37.9{\%} in T4; P=0.0485) and 75.1{\%} (vs. 35.5{\%} in N2-3 or T4; P=0.0002), respectively. No patients suffered from grade IV toxicities. In conclusion, the Azuma regimen may be a feasible option for patients with LN + disease. The use of intensive treatment in the pelvic area may serve an important role in outcome improvement, and the prevention of metastasis may be its mechanism.",
author = "Haruhito Azuma and Teruo Inamoto and Kiyoshi Takahara and Naokazu Ibuki and Hayahito Nomi and Kazumasa Komura and Hirofumi Uehara and Koichiro Minami and Kazuhiro Yamamoto and Yoshifumi Narumi",
year = "2019",
month = "1",
day = "1",
doi = "10.3892/ijo.2018.4619",
language = "English",
volume = "54",
pages = "167--176",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer. / Azuma, Haruhito; Inamoto, Teruo; Takahara, Kiyoshi; Ibuki, Naokazu; Nomi, Hayahito; Komura, Kazumasa; Uehara, Hirofumi; Minami, Koichiro; Yamamoto, Kazuhiro; Narumi, Yoshifumi.

In: International Journal of Oncology, Vol. 54, No. 1, 01.01.2019, p. 167-176.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer

AU - Azuma, Haruhito

AU - Inamoto, Teruo

AU - Takahara, Kiyoshi

AU - Ibuki, Naokazu

AU - Nomi, Hayahito

AU - Komura, Kazumasa

AU - Uehara, Hirofumi

AU - Minami, Koichiro

AU - Yamamoto, Kazuhiro

AU - Narumi, Yoshifumi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Overall, >900 patients have been treated at Osaka Medical College (Takatsuki, Osaka, Japan) using the novel approach of balloon-occluded arterial infusion (BOAI) to deliver an extremely high concentration of the anticancer agents cisplatin (CDDP)/gemcitabine to the pelvis (referred to as the OMC-regimen), together with pelvic irradiation. In a previous study, overall survival (OS) rate was significantly higher in this treatment group compared with that in a control group receiving total cystectomy (79.6 vs. 49.6%, respectively, at 10 years). It was speculated that intensive treatment of the pelvic area may aid in preventing metastasis, and thus the present study focused on the effect of this therapy in patients with lymph node metastasis (LN + ). A total of 102 patients with advanced LN + bladder cancer received tetramodal therapy (termed the Azuma regimen), comprising radical transurethral resection of the bladder tumor, systemic chemotherapy, BOAI and pelvic irradiation. Patients who failed to achieve a complete response (CR) underwent secondary BOAI with an increased amount of CDDP and/or gemcitabine with/without hemodialysis. A CR was achieved in 57.8% (59/102) of patients in total, and in 78.8% (41/52) of patients with N1 and Tis-3 disease. Among the complete responders, 81.4% (48/59) of patients retained their bladders with no evidence of recurrence or metastasis within a mean follow-up period of 121 weeks. Stages N2-3 and T4 were determined as significant risk factors for treatment failure in addition to survival. Notably, the 10-year overall survival rates in N1, Tis-3, and N1 and Tis-3 were 67.6% (vs. 33.6% in N2-3; P=0.0003), 61.5% (vs. 37.9% in T4; P=0.0485) and 75.1% (vs. 35.5% in N2-3 or T4; P=0.0002), respectively. No patients suffered from grade IV toxicities. In conclusion, the Azuma regimen may be a feasible option for patients with LN + disease. The use of intensive treatment in the pelvic area may serve an important role in outcome improvement, and the prevention of metastasis may be its mechanism.

AB - Overall, >900 patients have been treated at Osaka Medical College (Takatsuki, Osaka, Japan) using the novel approach of balloon-occluded arterial infusion (BOAI) to deliver an extremely high concentration of the anticancer agents cisplatin (CDDP)/gemcitabine to the pelvis (referred to as the OMC-regimen), together with pelvic irradiation. In a previous study, overall survival (OS) rate was significantly higher in this treatment group compared with that in a control group receiving total cystectomy (79.6 vs. 49.6%, respectively, at 10 years). It was speculated that intensive treatment of the pelvic area may aid in preventing metastasis, and thus the present study focused on the effect of this therapy in patients with lymph node metastasis (LN + ). A total of 102 patients with advanced LN + bladder cancer received tetramodal therapy (termed the Azuma regimen), comprising radical transurethral resection of the bladder tumor, systemic chemotherapy, BOAI and pelvic irradiation. Patients who failed to achieve a complete response (CR) underwent secondary BOAI with an increased amount of CDDP and/or gemcitabine with/without hemodialysis. A CR was achieved in 57.8% (59/102) of patients in total, and in 78.8% (41/52) of patients with N1 and Tis-3 disease. Among the complete responders, 81.4% (48/59) of patients retained their bladders with no evidence of recurrence or metastasis within a mean follow-up period of 121 weeks. Stages N2-3 and T4 were determined as significant risk factors for treatment failure in addition to survival. Notably, the 10-year overall survival rates in N1, Tis-3, and N1 and Tis-3 were 67.6% (vs. 33.6% in N2-3; P=0.0003), 61.5% (vs. 37.9% in T4; P=0.0485) and 75.1% (vs. 35.5% in N2-3 or T4; P=0.0002), respectively. No patients suffered from grade IV toxicities. In conclusion, the Azuma regimen may be a feasible option for patients with LN + disease. The use of intensive treatment in the pelvic area may serve an important role in outcome improvement, and the prevention of metastasis may be its mechanism.

UR - http://www.scopus.com/inward/record.url?scp=85056802488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056802488&partnerID=8YFLogxK

U2 - 10.3892/ijo.2018.4619

DO - 10.3892/ijo.2018.4619

M3 - Article

VL - 54

SP - 167

EP - 176

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -